Regulation - Pricing, InterMune


Current filters:


Popular Filters

UK's NICE gives final guidance on Esbriet, Orencia and Xolair


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData


Further research is a prerequisite to shine a light on idiopathic pulmonary fibrosis (IPF) and offer…

BiotechnologyEsbrietInterMunePricingRare diseasesRegulationResearch

Positive NICE news for GSK's Revolade and InterMune's Esbriet


UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

UK pharma group slams NICE for failing to recognize nature of discovery and development


The Association of the British Pharmaceutical Industry (ABPI) yesterday expressed major concern on behalf…


UK's NICE initially negative on InterMune's Esbriet for idiopathic pulmonary fibrosis


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) said yesterday that…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

French Transparency Commission issues favorable opinion on Esbriet


There was good news last week for USA-based InterMune (Nasdaq: ITMN) when the Transparency Commission…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Esbriet offers additional benefit, says German G-BA


USA-based InterMune (Nasdaq: ITMN) says that the German Federal Joint Committee (G-BA) has announced…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Back to top